Prostate Cancer Surgeons Quantify Erectile Function Recovery

Rockville, MD, May 08, 2009 --(PR.com)-- Blue Torch Medical Technologies, Inc. (BlueTorchMed.com) announced today that leading New York city doctors published a pivotal study on the company’s CaverMap® technology for erectile function recovery predictions. The results indicate that the CaverMap methods are an independent predictive tool to quantify erectile function recovery after prostate cancer surgery. The authors suggest that surgery with CaverMap provides a better process than a surgeon operating without the technology.

The March 2009 British Journal of Urology study is titled “Recovery of erectile function after radical prostatectomy is quantitatively related to the response to intraoperative cavernous nerve stimulation.” Memorial Sloan-Kettering Cancer Center urologists performed the study on 183 potent men who had radical prostatectomy with CaverMap cavernous nerve functional testing. The study indicated that stronger post-resection CaverMap responses related to greater erectile function recovery.

“This study verifies that applying CaverMap can predict prostate surgery results,” said Pete Zawadzki, Blue Torch’s Business Development Director. “It provides the foundation for further radical prostatectomy outcomes management research with a new focus on robotic surgery applications.”

Erectile dysfunction is a common side effect after prostate cancer surgery. Surgeons may apply CaverMap during radical prostatectomy to aid in locating and avoiding harm to the cavernous nerves, which control erectile function. CaverMap can help prevent nerve injury and now with this study, CaverMap may help guide further post-surgical treatment options. If you are considering prostate cancer surgery, ask your doctor about CaverMap, or contact Blue Torch for a referral.

###

The Blue Torch Medical Technologies, Inc.’s CaverMap® Surgical Aid is intended to provide stimulation to the body to locate and identify nerves and to test their excitability. The device is designed as an adjunct to the current open or laparoscopic prostatectomy and open colorectal procedures in which a nerve sparing technique is used. CaverMap is not designed to replace the surgeon’s expertise in mapping out the neurovascular bundles. The CaverMap Surgical Aid is available to assist physicians in preserving vital nerves during prostate cancer surgery and colorectal procedures.

Blue Torch Medical Technologies, Inc. is a privately held company with offices in Massachusetts and Maryland. This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans, or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this press release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Blue Torch Medical Technologies disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.